

Is noncurative gastrectomy always a beneficial strategy for stage IV gastric cancer?

Chang Min Lee^{1,2}, In Keun Choi^{3,4,*}, Jong-Han Kim^{1,2}, Da Won Park^{1,2}, Jun Suk Kim^{3,4}, Seong-Heum Park^{1,2}

¹Department of Surgery, Korea University Medical Center, Seoul, ²Department of Surgery, Korea University College of Medicine, Seoul, ³Department of Oncology, Korea University Medical Center, Seoul, ⁴Department of Oncology, Korea University College of Medicine, Seoul, Korea

Purpose: The purpose of this study is to suggest a treatment strategy for stage IV gastric cancer by investigating the behavioral difference between initially and recurrent metastatic disease.

Methods: We reviewed the medical records of the patients who underwent chemotherapy alone for metastatic gastric cancer between January 2006 and September 2013. Patients were divided into those who underwent chemotherapy for metastatic disease since initial diagnosis (IM group) and for metastatic recurrence after curative surgery (RM group). Survival and causes of death were compared between the 2 groups, and significant prognostic factors were also investigated.

Results: A total of 170 patients were enrolled in this study. Of these patients, 104 were included in the IM group and 66 in the RM group. Overall survival of the IM group did not differ from that of RM ($P = 0.569$). In the comparison of the causes of death, the IM group had a greater tendency to die from bleeding ($P = 0.054$) and pneumonia ($P = 0.055$). In multivariate analysis, bone metastasis ($P < 0.001$; HR = 2.847), carcinoma peritonei ($P = 0.047$; HR = 1.766), and the frequency of chemotherapy ($P < 0.001$; HR = 0.777) were significantly associated with overall survival of IM group.

Conclusion: Disease-burden mainly contributes to the prognosis of metastatic gastric cancer, although noncurative gastrectomy may be helpful in reducing the mortality of initially metastatic disease. Therefore, disease-burden should be also prioritized in determining the treatment strategies for stage IV gastric cancer.

[Ann Surg Treat Res 2017;92(1):23-29]

Key Words: Metastasis, Stomach neoplasms, Gastrectomy, Prognosis

INTRODUCTION

Although the prevalence of gastric cancer has recently decreased, it remains the third leading cause of cancer-related death [1]. This means that many patients still die due to incurable gastric cancer. In general, curability cannot be expected for metastatic gastric cancer [2].

However, some patients with metastatic disease show remarkably long survival [3-6]. Although such outcomes might be caused by aggressive treatments [7,8], it is necessary to evaluate the other clinicopathologic factors that can affect the prognosis of such patients. With respect to this issue, it is remarkable that metastatic gastric cancer includes two heterogenous disease

categories.

Based on whether curative resection was previously performed or not, metastatic gastric cancer can be classified into the 2 disease categories. One is initially metastatic disease with M1 factors, and the other is recurrent metastatic disease in which curative gastrectomy was previously performed. Each disease category is known to have a poor prognosis. In particular, initially metastatic disease is a representative feature of poor prognosis. According to data from the National Cancer Institute [9], the 5-year survival rate was 4.0% in patients with stage IV gastric cancer. Likewise, a good prognosis is also unlikely in patients with recurrent metastatic gastric cancer, despite the performance of previous curative surgery [10-12].

Received June 15, 2016, Revised August 18, 2016,
 Accepted September 7, 2016

Corresponding Author: Seong-Heum Park

Department of Surgery, Korea University College of Medicine, 73 Incheon-ro, Seongbuk-gu, Seoul 02841, Korea

Tel: +82-31-412-4936, Fax: +82-31-413-4829

E-mail: pshchw@korea.ac.kr

*Current address: Vision Medical School, Cameroon

Copyright © 2017, the Korean Surgical Society

© Annals of Surgical Treatment and Research is an Open Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Based on such previous reports, many physicians tend to regard both type of metastatic disease as having similar prognosis. Therefore, they have been managed both disease categories with chemotherapy alone. However, there has been no evidence to support such a similar treatment for both disease categories.

Some investigators described that surgical resection might cause a favorable prognosis through reduction of tumor-burden [13-16]. Considering these reports, recurrent metastatic gastric cancer is expected to have a smaller disease-burden than initially metastatic disease, because curative gastrectomy was performed before. Although chemotherapy can also lessen the disease-burden of initially metastatic disease, gastric lesions do not always show a dramatic response to chemotherapy. Even when tumors respond to a specific regimen, most eventually encounter drug resistance. In addition, remaining gastric tumors often lead to some critical problems, which may play a definite role in heightened mortality [17,18].

On the other hand, there are contradictory opinions regarding surgical treatment [19-21]. Reports in which surgery was recommended for stage IV gastric cancer have been criticized, because the candidates for surgical resection might have a smaller disease-burden or better performance status than the other patients with metastatic diseases [22]. In addition, while surgical treatment could reduce the disease-burden of advanced gastric cancer, dispersion of cancer cells into the peritoneal cavity may result [23]. With regard to such findings, initially metastatic gastric cancer might be associated with a better prognosis than recurrent metastatic disease, in which an unfavorable condition can be induced by previous surgery.

Based on these previous opinions, we established a hypothesis concerning the treatment strategy for stage IV gastric cancer. Although the previous investigators did not reach a consensus on the prognostic effect of surgery, a distinct difference between initially and recurrent metastatic gastric cancer was whether gastrectomy was performed or not. Therefore, the behavioral difference between the 2 disease may correlate with the prognostic effect of gastrectomy in stage IV disease.

In this study, we compared the prognosis and cause of death between patients with initially and recurrent metastatic gastric cancer in order to understand how gastrectomy affects the prognosis of stage IV disease.

METHODS

Between January 2006 and September 2013, the patients who underwent chemotherapy alone for metastatic gastric cancer at Korea University Ansan Hospital, South Korea were enrolled in this study. Enrolled cases satisfied the following criteria: (1) pathologically proven gastric adenocarcinoma, (2) considered to be M1 stage at the initial diagnosis or underwent metastatic recurrence after curative gastrectomy, and (3) without other

malignancy other than gastric cancer.

We collected records containing information regarding the clinicopathologic characteristics and treatment outcomes from those enrolled in the study. Patients were divided into 2 groups: Initially metastatic gastric cancer (IM) group and recurrent metastatic gastric cancer (RM) group. IM group included patients underwent chemotherapy for metastatic gastric cancer at the initial diagnosis, and RM group included patients who underwent chemotherapy for metastatic recurrence after curative surgery (The patients with gastric stump recurrence were excluded from RM group). Clinicopathologic outcomes including age, sex, serum CEA level, serum CA 19-9 level, degree of differentiation (by World Health Organization classification), distant lymph node metastasis, bone metastasis, lung metastasis, liver metastasis, carcinomatous peritonei, frequency of transfusion, frequency of chemotherapy, and dose reduction of chemotherapeutic drugs were investigated in each group. Clinicopathologic characteristics and causes of death were compared between the 2 groups using the chi-square test and independent Student t-test. Additionally, overall survival was calculated and compared between the 2 groups by using Kaplan-Meier method. Univariate and multivariate analyses were performed to investigate the significant prognostic factors using the Cox proportional hazard model.

IBM SPSS ver. 18.0 (IBM Co., Armonk, NY, USA) and R software ver. 2.15.2 (The R Project for Statistical Computing; available at <http://www.r-project.org/>) were used for statistical analyses.

This study was approved for research on human subjects by the Institutional Review Board of Korea University Ansan Hospital (approval number: AS16144).

RESULTS

Patient demographics and clinicopathologic outcomes

A total of 170 patients were enrolled in this study. The mean follow-up time was 336.9 ± 303.4 days (range, 6–2,207 days). Of these patients, 104 were included in IM group and 66 in the RM group. The scheme of enrollment is showed in Fig. 1.

The clinicopathologic characteristics of 2 groups are compared in Table 1. The 2 groups showed statistically significant difference in several factors: serum CEA level, presence of distant lymph node metastasis, presence of liver metastasis, frequency of chemotherapy cycles, number of cases underwent dose reduction.

Comparison of overall survival between the IM and RM groups

Overall survival of the IM group did not differ from that of the RM group ($P = 0.569$) (Fig. 2).




Fig. 1. Scheme of enrollment. IM, the patients underwent chemotherapy for initially metastatic gastric cancer; RM, the patients underwent chemotherapy for metastatic recurrence after surgical treatment.

Table 1. Demographics and clinicopathologic characteristics

Variable	IM group (n = 104)	RM group (n = 66)	P-value
Age (yr)	60.6 ± 12.1	57.0 ± 13.6	0.077
Sex, male:female	2.25:1	2:1	0.726
Serum CEA level	183.1 ± 792.8	23.5 ± 86.8	0.051
Serum CA 19-9 level	408.0 ± 1742.8	542.4 ± 1647.2	0.624
WHO classification (%)			0.872
Well differentiated	5.8	3.0	
Moderately differentiated	33.7	34.8	
Poorly differentiated	46.2	47.0	
Signet ring cell	12.5	13.6	
Distant lymph node metastasis (%)	92.3	66.7	<0.001
Bone metastasis (%)	23.1	12.1	0.075
Lung metastasis (%)	8.7	6.1	0.535
Liver metastasis (%)	41.3	16.7	0.001
Carcinomatosis peritonei (%)	53.8	40.9	0.100
Frequency of transfusions ^{a)}	4.7 ± 6.9	5.7 ± 7.9	0.414
Frequency of chemotherapy ^{b)}	9.0 ± 5.4	6.9 ± 5.4	0.013
No. of chemotherapy lines ^{c)}	2.4 ± 1.4	2.1 ± 1.2	0.119
Cases underwent dose reduction ^{d)} (%)	49.0	31.8	0.027

Values are presented as mean ± standard deviation or number unless otherwise indicated.

IM, the patients underwent chemotherapy for initially metastatic gastric cancer; RM, the patients underwent chemotherapy for metastatic recurrence after surgical treatment; WHO, World Health Organization.

^{a)}This number means the number of packed blood cells which is transfused to the patients. ^{b)}This number means the number of cycles with which chemotherapy was performed. ^{c)}This number means the number of lines with which chemotherapy was performed. ^{d)}This number means the number of cases in which the dose of chemotherapeutic drugs was reduced during chemotherapy.

Causes of death in the IM and RM groups

In the comparison of the causes of death, the IM group had a greater tendency to die of bleeding (P = 0.054) or pneumonia (P = 0.055) compared to the RM group did (Table 2).

As a supplement analysis, when pneumonia was further

classified into 'aspiration pneumonia' and 'nonaspiration pneumonia', the IM group included 7 cases (6.7%) of aspiration pneumonia and RM group 1 case (1.5%). However, this difference was not statistically significant (P = 0.118) (Table 2).

Prognostic factors affecting overall survival in IM and RM groups

In multivariate analysis, bone metastasis ($P < 0.001$; HR = 2.847), carcinoma peritonei ($P = 0.047$; HR = 1.766), and

the frequency of chemotherapy ($P < 0.001$; HR = 0.777) were significantly associated with overall survival of IM group (Table 3). In RM group, the serum CA 19-9 level ($P = 0.012$; HR = 1.000), the frequency of transfusion ($P = 0.034$; HR = 1.044) correlated with overall survival (Table 4).




Fig. 2. Comparison of overall survival between IM and RM groups. Overall survival did not differ between the 2 groups ($P = 0.569$, by log-rank test). IM, the patients underwent chemotherapy for initially metastatic gastric cancer; RM, the patients underwent chemotherapy for metastatic recurrence after surgical treatment.

Table 2. Causes of death in the IM and RM groups

Variable	IM group ^{a)} (n = 104)	RM group (n = 66)	P-value
Progression of disease (%)	15.4	22.7	0.227
Thromboembolism (%)	2.9	7.6	0.159
Perforation of stomach or bowel (%)	1.9	4.5	0.324
Bleeding (%)	8.7	1.5	0.054
Obstruction (%)	3.8	1.5	0.381
Pneumonia (%)	22.1	10.6	0.055
With aspiration history	6.7	1.5	0.118
Without aspiration history	15.4	9.1	0.233
Miscellaneous (%)	6.7	13.6	0.133

IM, the patients underwent chemotherapy for initially metastatic gastric cancer; RM, the patients underwent chemotherapy for metastatic recurrence after surgical treatment.

^{a)}IM group had more tendency to die because of bleeding ($P = 0.054$) and pneumonia ($P = 0.055$).

Table 3. Investigation of prognostic factors in the IM groups (n = 104)

Variable	Univariate analysis		Multivariate analysis ^{e)}		
	HR	P-value	HR	95% CI	P-value
Age	0.995	0.673			
Sex	1.541	0.108			
Serum CEA level	1.000	0.424			
Serum CA 19-9 level	1.000	0.345			
WHO classification					
Well differentiated	1	0.062			
Moderately differentiated	1.667	0.495			
Poorly differentiated	3.115	0.122			
Signet ring cell	4.095	0.080			
Distant lymph node metastasis	0.603	0.212			
Bone metastasis	2.166	0.006	2.847	1.591–5.093	<0.001
Lung metastasis	0.425	0.150			
Liver metastasis	0.537	0.023	0.733	0.416–1.292	0.282
Carcinomatosis peritonei	2.177	0.004	1.766	1.008–3.092	0.047
Frequency of transfusion ^{a)}	1.006	0.760			
Frequency of chemotherapy ^{b)}	0.822	<0.001	0.777	0.707–0.853	<0.001
No. of chemotherapy lines ^{c)}	0.697	<0.001	1.186	0.907–1.551	0.212
Dose reduction ^{d)}	1.357	0.230			

IM, the patients underwent chemotherapy for inoperable advanced gastric cancer at the initial diagnosis; HR, hazard ratio; CI, confidence interval; WHO, World Health Organization.

^{a)}The number of packed red cells which was transfused to the patients. ^{b)}The number of cycles with which chemotherapy was performed. ^{c)}The number of lines with which chemotherapy was performed. ^{d)}This means whether the dose of chemotherapeutic drugs was reduced during chemotherapy. ^{e)}Multivariate analysis showed that bone metastasis, carcinoma peritonei, and the frequency of chemotherapy were independent risk factors for cancer-related death.

DISCUSSION

In the current study, behavioral differences were compared between patients with initially and recurrent metastatic gastric cancer. As a result, survival did not differ between the 2 disease categories (Fig. 2); however, the 2 disease categories showed different tendencies regarding causes of death (Table 2). Although a P-value greater than 0.05 provided limited significance, the patients of IM group had greater tendency to die from bleeding or pneumonia than did RM group. We contemplated that this tendency might be caused by the remaining gastric lesions of IM group. In fact, as initially metastatic cases did not undergo gastrectomy before, they embed the potential to cause the following complications: First, the remaining gastric lesion of initially metastatic case is at a high risk of bleeding or perforation. Second, if the gastric lesion grows enough to cause obstruction or stasis, the patient is predisposed to aspiration pneumonia [24-27]. Our data also included more patients who died of aspiration pneumonia in IM group, even though comparative analysis did not reach a statistically significant difference (Table 2).

On the contrary, RM group was free from the gastric lesions, since we excluded the patients with gastric stump recurrence

from this study (Fig. 1). Consequently, these patients might rarely encounter clinical crisis such as primary tumor bleeding, gastric outlet obstruction, and gastric perforation. In regard to these issue, we previously reported that 'noncurative surgery' delayed the time at which palliative procedures (e.g., endoscopic bleeding control or stent insertion) should be performed [28]. Therefore, when focusing on our results regarding causes of death, noncurative surgery can be a solution for stage IV gastric cancer [28,29].

However, we failed to explain how surgery affects the prognosis of initially metastatic cases. Most of all, the previous history of gastrectomy did not cause any survival gain of recurrent metastatic cases, as we found no prognostic difference between IM and RM groups. In addition, when we investigated the clinical courses of stage IV patients who died of bleeding or pneumonia, these cases also embedded other mortality-related conditions regardless of gastric lesions (data not shown). Therefore, we should find the other factors that affected the prognosis in each group.

As shown in Tables 3 and 4, bone metastasis, carcinoma peritonei, and frequency of chemotherapy were revealed as significant prognostic factors in the IM group, while these factors had no significant prognostic effect in the RM group.

Table 4. Investigation of prognostic factors in the RM groups (n = 66)

Variable	Univariate analysis		Multivariate analysis ^{e)}		
	HR	P-value	HR	95% CI	P-value
Age	0.985	0.158	-	-	
Sex	1.920	0.051	-	-	
Serum CEA level	1.004	0.137	-	-	
Serum CA 19-9 level	1.000	0.012	1.000	1.000–1.000	0.012
WHO classification					
Well differentiated	1.000	0.342	-	-	
Moderately differentiated	2.820	0.325	-	-	
Poorly differentiated	4.079	0.170	-	-	
Signet ring cell	2.378	0.425	-	-	
Distant lymph node metastasis	1.126	0.732	-	-	
Bone metastasis	1.869	0.166	-	-	
Lung metastasis	0.354	0.308	-	-	
Liver metastasis	0.773	0.590	-	-	
Carcinomatosis peritonei	1.128	0.704	-	-	
Frequency of transfusion ^{a)}	1.048	0.020	1.044	1.033–1.087	0.034
Frequency of chemotherapy ^{b)}	0.940	0.038	0.950	0.897–1.007	0.084
Number of chemotherapy lines ^{c)}	1.004	0.971	-	-	
Dose reduction ^{d)}	1.278	0.461	-	-	

RM, the patients underwent chemotherapy for metastatic recurrence after surgical treatment; HR, hazard ratio; CI, confidence interval; WHO, World Health Organization.

^{a)}The number of packed red cells which was transfused to the patients. ^{b)}The number of cycles with which chemotherapy was performed. ^{c)}The number of lines with which chemotherapy was performed. ^{d)}This means whether the dose of chemotherapeutic drugs was reduced during chemotherapy. ^{e)}Multivariate analysis showed that the serum CA 19-9 level and frequency of transfusion were independent risk factors for cancer-related death.

Although both disease categories similarly showed incurable features, different prognostic factors affected each disease. In addition, even though the remaining gastric tumor increased some types of cancer-related death in the IM group (Table 2), the prognostic effect of such mortalities might be overwhelmed by the heavy "disease-burden" (e.g., bone metastasis or carcinoma peritonei). In other words, disease-burden may have a more significant effect on the prognosis of stage IV disease than noncurative gastrectomy.

Moreover, frequency of chemotherapy also attracted attention as a strong prognostic factor in the IM group (Table 3). In particular, it was inspirable that "dose reduction" or "number of chemotherapy lines" was not a significant prognostic factor. This result implied that the steady performance was the most important factor in chemotherapy for stage IV gastric cancer.

Considering all these results, we can contemplate a principle of planning treatment strategies for stage IV gastric cancer.

As indicated in the previous reports, some investigators assure as if palliative gastrectomy induces survival gain in

initially metastatic gastric cancer [13-16]. However, as shown in our results, the benefit of noncurative surgery could not outweigh the prognostic effect of disease-burden. Although noncurative gastrectomy improved the general condition in some cases, an impellent surgery may cause a fatal mistake of delaying chemotherapy in patients with bone metastasis or peritoneal seeding. With regard to this issue, the recent results of a randomized controlled trial also showed that noncurative surgery can decrease chemotherapy compliance without any prognostic benefit [30]. Furthermore, according to our data, the type of noncurable factor was significantly correlated to the prognosis of stage IV disease. Therefore, disease-burden should be prioritized in planning treatment strategies for stage IV gastric cancer.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015;136: E359-86.
2. Lehnert T, Rudek B, Buhl K, Golling M. Surgical therapy for loco-regional recurrence and distant metastasis of gastric cancer. *Eur J Surg Oncol* 2002;28:455-61.
3. Kita K, Takahashi M, Nakano S, Akabane H, Yanagida N, Shomura H, et al. A case of long-term survival of unresectable-advanced gastric cancer due to chemotherapy. *Gan To Kagaku Ryoho* 2009;36: 2281-3.
4. Tanida T, Aoki T, Igarashi Y, Tsukao Y, Komori T, Matsumoto T, et al. Two cases of long-term survival with CY1, stage IV gastric cancer due to surgery and post-operative chemotherapy. *Gan To Kagaku Ryoho* 2008;35:2063-5.
5. Tomimatsu H, Nakano T. Two cases of stage IV gastric cancer who underwent total gastrectomy and achieved long-term survival by sequential chemotherapy. *Gan To Kagaku Ryoho* 2007;34:2291-5.
6. Hibi Y, Takagi Y, Hoshino S, Katayanagi S, Sudo H, Suda T, et al. Long survival and effective treatment of unresectable gastric cancer by TS-1 based chemotherapy with a sequential combination. *Gan To Kagaku Ryoho* 2007;34:257-60.
7. Shinohara S, Korenaga D, Edagawa A, Koushi K, Itoh S, Kawanaka H, et al. Significant prognostic factors in patients with Stage IV gastric cancer with special reference to the curability of surgery. *Surg Today* 2013;43:40-7.
8. Yagi Y, Seshimo A, Kameoka S. Prognostic factors in stage IV gastric cancer: univariate and multivariate analyses. *Gastric Cancer* 2000;3:71-80.
9. Washington K. 7th edition of the AJCC cancer staging manual: stomach. *Ann Surg Oncol* 2010;17:3077-9.
10. Hwang SE, Yang DH, Kim CY. Prognostic factors for survival in patients with hepatic recurrence after curative resection of gastric cancer. *World J Surg* 2009;33:1468-72.
11. Kim JH, Jang YJ, Park SS, Park SH, Mok YJ. Benefit of post-operative surveillance for recurrence after curative resection for gastric cancer. *J Gastrointest Surg* 2010; 14:969-76.
12. Kodera Y, Ito S, Yamamura Y, Mochizuki Y, Fujiwara M, Hibi K, et al. Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. *Ann Surg Oncol* 2003;10:898-902.
13. Chang YR, Han DS, Kong SH, Lee HJ, Kim SH, Kim WH, et al. The value of palliative gastrectomy in gastric cancer with distant metastasis. *Ann Surg Oncol* 2012;19:1231-9.
14. Zhang JZ, Lu HS, Huang CM, Wu XY, Wang C, Guan GX, et al. Outcome of palliative total gastrectomy for stage IV proximal gastric cancer. *Am J Surg* 2011;202:91-6.
15. Mariette C, Bruyere E, Messenger M, Pichot-Delahaye V, Paye F, Dumont F, et al. Palliative resection for advanced gastric and junctional adenocarcinoma: which patients will benefit from surgery? *Ann Surg Oncol* 2013;20:1240-9.
16. Jeong O, Park YK, Choi WY, Ryu SY. Prognostic significance of non-curative gas-

- trectomy for incurable gastric carcinoma. *Ann Surg Oncol* 2014;21:2587-93.
17. Pereira J, Phan T. Management of bleeding in patients with advanced cancer. *Oncologist* 2004;9:561-70.
 18. Vasas P, Wiggins T, Chaudry A, Bryant C, Hughes FS. Emergency presentation of the gastric cancer; prognosis and implications for service planning. *World J Emerg Surg* 2012;7:31.
 19. Ouchi K, Sugawara T, Ono H, Fujiya T, Kamiyama Y, Kakugawa Y, et al. Therapeutic significance of palliative operations for gastric cancer for survival and quality of life. *J Surg Oncol* 1998;69:41-4.
 20. Kokkola A, Louhimo J, Puolakkainen P. Does non-curative gastrectomy improve survival in patients with metastatic gastric cancer? *J Surg Oncol* 2012;106:193-6.
 21. Schmidt B, Look-Hong N, Maduekwe UN, Chang K, Hong TS, Kwak EL, et al. Noncurative gastrectomy for gastric adenocarcinoma should only be performed in highly selected patients. *Ann Surg Oncol* 2013;20:3512-8.
 22. Lasithiotakis K, Antoniou SA, Antoniou GA, Kaklamanos I, Zoras O. Gastrectomy for stage IV gastric cancer. a systematic review and meta-analysis. *Anticancer Res* 2014;34:2079-85.
 23. Takebayashi K, Murata S, Yamamoto H, Ishida M, Yamaguchi T, Kojima M, et al. Surgery-induced peritoneal cancer cells in patients who have undergone curative gastrectomy for gastric cancer. *Ann Surg Oncol* 2014;21:1991-7.
 24. Sabharwal T, Irani FG, Adam A: Cardiovascular and Interventional Radiological Society of Europe. Quality assurance guidelines for placement of gastroduodenal stents. *Cardiovasc Intervent Radiol* 2007; 30:1-5.
 25. Jung GS, Song HY, Kang SG, Huh JD, Park SJ, Koo JY, et al. Malignant gastroduodenal obstructions: treatment by means of a covered expandable metallic stent-initial experience. *Radiology* 2000;216:758-63.
 26. Bessoud B, de Baere T, Denys A, Kuoch V, Ducreux M, Precetti S, et al. Malignant gastroduodenal obstruction: palliation with self-expanding metallic stents. *J Vasc Interv Radiol* 2005;16(2 Pt 1):247-53.
 27. Mansoor H, Yusuf MA. Outcomes of endoscopic pyloric stenting in malignant gastric outlet obstruction: a retrospective study. *BMC Res Notes* 2013;6:280.
 28. Park SH, Kim JH, Park JM, Park SS, Kim SJ, Kim CS, et al. Value of nonpalliative resection as a therapeutic and pre-emptive operation for metastatic gastric cancer. *World J Surg* 2009;33:303-11.
 29. Miner TJ, Jaques DP, Karpeh MS, Brennan MF. Defining palliative surgery in patients receiving noncurative resections for gastric cancer. *J Am Coll Surg* 2004; 198:1013-21.
 30. Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. *Lancet Oncol* 2016;17:309-18.